Repare Therapeutics Doses First Subject in Phase I Solid Tumour Trial
LifeSci Capital Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $8
Repare Begins Clinical Trial Combining RP-3467 and PARP Inhibitor Olaparib to Fight Advanced Cancers
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Express News | Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of Rp-3467, a PolΘ Atpase Inhibitor
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Stifel Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)
Morgan Stanley Maintains Repare Therapeutics(RPTX.US) With Hold Rating, Maintains Target Price $8
Hold Rating on Repare Therapeutics Amidst Early Promising Clinical Results and Safety Concerns
Stocks to Watch: CVS Health, PepsiCo, Repare Therapeutics
Repare Therapeutics Gets Encouraging Early Phase 1 Data for Camonsertib
12 Health Care Stocks Moving In Monday's After-Market Session
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination With Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Express News | Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination With Radiotherapy Treatment Presented at the Astro Annual Meeting
Repare Therapeutics Inc. (NASDAQ:RPTX) Is Definitely on the Radar of Institutional Investors Who Own 36% of the Company
Express News | Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients With Metastatic Gynecologic Cancers
HC Wainwright & Co. Reiterates Buy on Repare Therapeutics, Maintains $10 Price Target
Piper Sandler Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $25
Piper Sandler analyst Joseph Catanzaro maintains $Repare Therapeutics(RPTX.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 4